Effect of Qingfei Paidu decoction combined with Western medicine treatments for COVID-19: A systematic review and meta-analysis

Zhang, Lei; Ma, Yan; Shi, Nannan; Lin, Tong; Liu, Sihong; Ji, Xinyu; Chen, Renbo; Fan, Yipin; Liang, Ning; Ge, Youwen; Gao, Hongjie; Chen, Guangkun; Wang, Wei; Zhang, Huamin; Wang, Yanping; Wang, Yongyan

doi:10.1016/j.phymed.2022.154166

Cited by 15 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we concluded that QFPDD might help improve the clinical symptoms of COVID-19 patients with other respiratory diseases; no serious adverse events related to QFPDD were observed, which was in line with previous studies ( Wang J. et al, 2021 ; Wang Q. et al, 2021 ; Chen et al, 2021 ; Zhang et al, 2021 ; Zhang et al, 2022 ). The results of this study may provide a reference for clinicians to use QFPDD treatment.…”

Section: Discussionsupporting

confidence: 91%

“…In addition, it also had inspiring effects on the treatment of COVID-19, and early treatment with Qingfei Paidu decoction (QFPDD) was associated with favorable outcomes ( Shi et al, 2020 ; Ma et al, 2020 ). Moreover, two systematic reviews and meta-analyses demonstrated the effectiveness and safety of QFPDD in treating COVID-19 patients ( Wang J. et al, 2021 ; Zhang et al, 2022 ). Since the sixth version of the national guideline Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia has been issued, QFPDD has been recommended as a general formula for the treatment of all COVID-19 patients including mild, moderate, severe, and critically ill cases.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case Series

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Qingfei Paidu decoction (QFPDD) has been widely used in treating coronavirus disease 2019 (COVID-19) in China. However, studies on the treatment effect of COVID-19 patients and other respiratory diseases have not been well demonstrated. Our study aims to determine the treatment effect of QFPDD in combination with conventional treatment on COVID-19 patients and other respiratory diseases.Methods: This retrospective study recruited COVID-19 patients who were treated with QFPDD for at least two courses (6 days) from seven hospitals in five provinces from January 21 to March 18 2020. Demographic, epidemiological, clinical, laboratory, computed tomography characteristics, treatment, and outcome data were collected and analyzed. The improvements in clinical symptoms before and after QFPDD treatment were compared.Results: Eight COVID-19 patients were included in this study. Of them, six were males (75.0%). The median age of the patients was 66 (60–82) years. Four patients were classified as mild and moderate cases (50.0%); there were two severe cases (25.0%) and critical cases (25.0%). The most common symptom was cough (7 [87.5%]), followed by fever (6 [75.0%]), fatigue (4 [50.0%]), asthma (4 [50.0%]), and anorexia (3 [37.5%]). Abnormal findings included decrease in neutrophils (3 [37.5%]), lymphocytes (2 [25.0%]), alkaline phosphatase (3 [37.5%]), lactic dehydrogenase (4 [50.0%]), erythrocyte sedimentation rate (2 [25.0%]), and C-reactive protein (5 [83.3%]) at admission. After one course (3 days) of QFPDD, nasal obstruction and sore throat completely disappeared, and fever (5 [83.3%]), fatigue (2 [50.0%]), and cough (2 [28.6%]) were improved. After two courses (6 days), the fever disappeared completely in all patients, and the other symptoms showed a tendency to improve. In non-severe patients, 87.5% baseline symptoms completely disappeared. In severe patients, 61.1% of the baseline symptoms completely disappeared after patients were administered QFPDD for two courses. Of the abnormal indicators, 55.6% returned to normal levels. The median duration to complete fever recovery was 1.0 day. The median durations of viral shedding and hospitalization were 10.5 and 21.5 days, respectively. None of the patients worsened and died, and no serious adverse events occurred related to QFPDD during hospitalization.Conclusion: QFPDD combined with conventional treatment improved clinical symptoms in COVID-19 patients with other respiratory diseases, and no serious adverse reactions associated with QFPDD were observed. Larger sample studies confirm our findings in the future.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case Series

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“… 23 Based on TCM theory, three Chinese patent medicines (including Lianhua Qingwen Capsule, Jinhua Qinggan Granules, and Xuebijing Injection) as well as three herbal prescriptions (including Xuanfeibaidu Recipe, Huashi Paidu Recipe, and Qingfei Paidu Decoction) have been identified to prevent the transmission of SARS-CoV-2 and to treat COVID-19. 8 So far, more and more clinical evidences have suggested the inspiring effectiveness and safety of these prescriptions of Chinese herbs such as Qingfei Paidu Decoction, 21 , 22 Lianhua Qingwen Capsule 24 , 25 and Huashi Paidu Recipe 26 in controlling COVID-19. Moreover, the potential anti-SARS-CoV-2 characteristics of some single Chinese herbs particularly attracted increasing interest of scientists.…”

Section: Introductionmentioning

confidence: 99%

“…16,20 To control the current COVID-19 pandemic in China, the Chinese government has implemented multiple effective strategies, among which the application of traditional Chinese herbal formulas has been officially recommended in the national Guideline of Diagnosis and Treatment Plan for COVID-19 as an important complement to conventional treatment for different phases of COVID-19, including mild, moderate, severe, even critically ill patients. 7,9,[21][22][23] The Chinese state media and medical experts also strongly promoted the idea of using traditional Chinese herbal medicine as an integral part of the COVID-19 control plan. 23 Based on TCM theory, three Chinese patent medicines (including Lianhua Qingwen Capsule, Jinhua Qinggan Granules, and Xuebijing Injection) as well as three herbal prescriptions (including Xuanfeibaidu Recipe, Huashi Paidu Recipe, and Qingfei Paidu Decoction) have been identified to prevent the transmission of SARS-CoV-2 and to treat COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Practices, Knowledge, and Attitudes of Chinese University Students Toward Traditional Chinese Herbal Medicine for the Control of COVID-19

Li¹,

Liu²,

Hu³

et al. 2022

IDR

View full text Add to dashboard Cite

Background The application of traditional Chinese herbal medicine has been officially recommended and strongly promoted in China as an important complement to conventional prevention and treatment for COVID-19. Capturing the practices, knowledge and attitudes of young adult population toward using Chinese herbs for COVID-19 is important for understanding the future of Chinese herbal medicine over the coming decades. Methods This cross-sectional questionnaire-based study was conducted from May to June, 2022, among 313 student volunteers in Wuhan University of Science and Technology, a provincial comprehensive university in China. Results Results showed that only 18% of students had used Chinese herbs to prevent COVID-19. The main information sources were social media, the students’ family members, relatives, friends, etc. as well as the healthcare professionals. However, most students only sometimes paid close attention to related reports and news articles in social media. Clear pharmacological and toxicological properties of herbs were considered by 43% students as the most important factor to promote their own application of Chinese herbs to fight COVID-19. The mean knowledge score was 1.64 out of 5. Students’ overall attitudes toward application of Chinese herbal medicine to fight COVID-19 were very positive. Conclusion These data suggests most university young adults had a positive attitude but lack of practices and knowledge towards traditional Chinese herbal medicine for COVID-19 control.

show abstract

“…Lianhua Qingwen capsules, supplied during the COVID-19 pandemic in Shanghai in 2022, shared the major ingredients of Shuang and Lian, while Qingfei Paidu decoction shared the major ingredient of Huang. 49, 50 Moreover, the involved ingredients, such as Atractylodes macrocephala Koidz, Belamcanda chinensis (L.) Redouté, and Citrus reticulata Blanco, contained similar components as those found in Shuanghuanglian.…”

Section: Similarity In the Compounds And Ingredientsmentioning

confidence: 93%

Virtual Screening of Shuanghuanglian Components for the Binding to the Proteinases of SARS-CoV-2

Yang¹,

Ainiwaer²,

Wang³

et al. 2022

J Explor Res Pharmacol

View full text Add to dashboard Cite

Background and objectives: Coronavirus disease 2019 (COVID-19), a global pandemic disease caused by SARS-CoV2 infection, has existed for nearly three years. However, there are currently only a few therapeutic drugs available. The objective of this study attempted to explore the potential therapeutic actions of Shuanghuanglian, a traditional Chinese medicine, using molecular docking simulation technology. Methods:The ingredients of Shuanghuanglian and the approved drugs were structurally evaluated. The potential bindings of the individual ingredients in Shuanghuanglian to the PLPro and Mpro of the SARS-CoV2 were evaluated by molecular docking simulation according to the energy parameters. The corresponding binding patterns into each defined site were analyzed. The pharmacokinetics of the individual ingredients were predicted to preliminarily evaluate their oral bioavailability.Results: There were 482 unique natural products in the categories of fatty acids, aromatic compounds, glycosides, and sterols. The successfully docked rates of the Shuanghuanglian components binding to the PLPro and Mpro were all higher than that of the compounds in the Food and Drug Administration-approved Drug Library. In general, Shuang and Lian took the primary status in providing the top hits via the hydrogen bonds, while Huang acted as an important supplement to the global activity. Though the selected hits faced the common difficulty of polarity, the deglycosylation and the package by the carriers could also be practical to overcome the pharmacokinetic violation. Conclusions:Shuang and Lian retained the potential ability to interact with the PLPro and Mpro of SARS-CoV2, and other

show abstract

Effect of Qingfei Paidu decoction combined with Western medicine treatments for COVID-19: A systematic review and meta-analysis

Cited by 15 publications

References 42 publications

Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case Series

Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case Series

Practices, Knowledge, and Attitudes of Chinese University Students Toward Traditional Chinese Herbal Medicine for the Control of COVID-19

Virtual Screening of Shuanghuanglian Components for the Binding to the Proteinases of SARS-CoV-2

Contact Info

Product

Resources

About